CST1在胃癌进展中的作用机制及临床意义

doi:10.3760/cma.j.cn371439-20230308-00093

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (8): 489-492.doi: 10.3760/cma.j.cn371439-20230308-00093

CST1在胃癌进展中的作用机制及临床意义

邵慧芳¹, 王学红², 芦永福²()

¹ 青海大学研究生院，西宁 810016
² 青海大学附属医院消化内科，西宁 810001

收稿日期:2023-03-08 修回日期:2023-03-25 出版日期:2023-08-08 发布日期:2023-10-24
通讯作者: 芦永福 E-mail:gyxb123@163.com
基金资助:
青海大学附属医院院级重点学科建设项目(青大附医政字〔2019〕195号)

Mechanism of action and clinical significance of CST1 in the progression of gastric cancer

Shao Huifang¹, Wang Xuehong², Lu Yongfu²()

¹ Graduate School of Qinghai University, Xining 810016, China
² Department of Gastroenterology, Affiliated Hospital of Qinghai University, Xining 810001, China

Received:2023-03-08 Revised:2023-03-25 Online:2023-08-08 Published:2023-10-24
Contact: Lu Yongfu E-mail:gyxb123@163.com
Supported by:
Hospital-Level Key Discipline Construction Project of the Affiliated Hospital of Qinghai University(〔2019〕195)

摘要/Abstract

摘要：

半胱氨酸蛋白酶抑制剂1（CST1）是2型Cystatins超家族成员之一，在靶向调节中起关键的作用。CST1在胃癌中呈现高表达，通过激活上皮-间质转化通路、Wnt信号通路促进肿瘤细胞的迁移和侵袭，并与同源盒C10、谷胱甘肽过氧化物酶4相应靶基因结合调控肿瘤生长和发展。深入了解CST1在胃癌中的作用和功能，有助于进一步开发针对胃癌的潜在治疗靶点和诊断及预后标志物。

关键词: 胃肿瘤, 半胱酸蛋白酶抑制剂1

Abstract:

Cysteine protease inhibitor 1 （CST1） is a member of type 2 Cystatins superfamily, plays a key role in targeted regulation. CST1 is highly expressed in gastric cancer, promotes tumor cell migration and invasion by activating the epithelial-mesenchymal transformation pathway and Wnt pathway, and regulates tumor growth and progression in combination with the corresponding target genes of homeobox C10 and glutathione peroxidase 4. A deeper understanding of the role and function of CST1 in gastric cancer will help to further develop potential therapeutic targets and diagnostic and prognostic markers for gastric cancer.

Key words: Stomach neoplasms, Cysteine protease inhibitor 1

邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.

Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492.

参考文献 28

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI:10.3322/caac.21660.
[2]	Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins[J]. Biochem Soc Symp, 2003, 70: 179-199. DOI:10.1042/bss0700179.
[3]	Anastasi A, Brown MA, Kembhavi AA, et al. Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum[J]. Biochem J, 1983, 211(1): 129-138. DOI:10.1042/bj2110129. pmid: 6409085
[4]	Delimont NM, Nickel S. Salivary cystatin SN is a factor predicting iron bioavailability after phytic acid rich meals in female participants[J]. Int J Food Sci Nutr, 2021, 72(4): 559-568. DOI:10.1080/09637486.2020.1846164.
[5]	de Sousa-Pereira P, Amado F, Abrantes J, et al. An evolutionary perspective of mammal salivary peptide families: cystatins, histatins, statherin and PRPs[J]. Arch Oral Biol, 2013, 58(5): 451-458. DOI:10.1016/j.archoralbio.2012.12.011. pmid: 23352445
[6]	Dickinson DP, Thiesse M, Dempsey LD, et al. Genomic cloning, physical mapping, and expression of human type 2 cystatin genes[J]. Crit Rev Oral Biol Med, 1993, 4(3/4): 573-580. DOI:10.1177/10454411930040034401.
[7]	陈涛. CST1促进胃癌转移的作用及其机制研究[D]. 苏州: 苏州大学, 2021. DOI:10.27351/d.cnki.gszhu.2021.001853.
[8]	Liu Y, Yao J. Research progress of cystatin SN in cancer[J]. Onco Targets Ther, 2019, 12: 3411-3419. DOI:10.2147/OTT.S194332.
[9]	Tian S, Peng P, Li J, et al. SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway[J]. Aging (Albany NY), 2020, 12(4): 3574-3593. DOI:10.18632/aging.102831.
[10]	Bure IV, Nemtsova MV, Zaletaev DV. Roles of E-cadherin and noncoding RNAs in the epithelial-mesenchymal transition and progression in gastric cancer[J]. Int J Mol Sci, 2019, 20(12): 2870. DOI:10.3390/ijms20122870.
[11]	Cui Y, Sun D, Song R, et al. Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis[J]. J Cell Physiol, 2019, 234(12): 22623-22634. DOI:10.1002/jcp.28828. pmid: 31106426
[12]	Yang J, Luo G, Li C, et al. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma[J]. BMC Cancer, 2022, 22(1): 589. DOI:10.1186/s12885-022-09685-z. pmid: 35637432
[13]	Chen S, Liu Y, Zhang K, et al. CST1 promoted gastric cancer migration and invasion through activating Wnt pathway[J]. Cancer Manag Res, 2021, 13: 1901-1907. DOI:10.2147/CMAR.S277770. pmid: 33658852
[14]	Taciak B, Pruszynska I, Kiraga L, et al. Wnt signaling pathway in development and cancer[J]. J Physiol Pharmacol, 2018, 69(2): 185-196. DOI:10.26402/jpp.2018.2.07.
[15]	Clements WM, Wang J, Sarnaik A, et al. β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer[J]. Cancer Res, 2002, 62(12): 3503-3506. pmid: 12067995
[16]	Kang MH, Choi H, Oshima M, et al. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer[J]. Nat Commun, 2018, 9(1): 1920. DOI:10.1038/s41467-018-04244-2.
[17]	Fang J, Wang J, Yu L, et al. Role of HOXC10 in cancer[J]. Front Oncol, 2021, 11: 684021. DOI:10.3389/fonc.2021.684021.
[18]	Keppler D, Zhang J, Bihani T, et al. Novel expression of CST1 as candidate senescence marker[J]. J Gerontol A Biol Sci Med Sci, 2011, 66(7): 723-731. DOI:10.1093/gerona/glr033.
[19]	Peng Y, Li Y, Li Y, et al. HOXC10 promotes tumour metastasis by regulating the EMT-related gene Slug in ovarian cancer[J]. Aging (Albany NY), 2020, 12(19): 19375-19398. DOI:10.18632/aging.103824.
[20]	Zhang X, Zheng Y, Liu X, et al. The expression of HOXC10 is correlated with tumor-infiltrating immune cells in basal-like breast cancer and serves as a prognostic biomarker[J]. Ann Transl Med, 2022, 10(2): 81. DOI:10.21037/atm-21-6611.
[21]	Kim J, Bae DH, Kim JH, et al. HOXC10 overexpression promotes cell proliferation and migration in gastric cancer[J]. Oncol Rep, 2019, 42(1): 202-212. DOI:10.3892/or.2019.7164. pmid: 31115563
[22]	Xu C, Liu Z, Xiao J. Ferroptosis: a double-edged sword in gastrointestinal disease[J]. Int J Mol Sci, 2021, 22(22): 12403. DOI:10.3390/ijms222212403.
[23]	Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis[J]. Proteomics, 2019, 19(18): e1800311. DOI:10.1002/pmic.201800311.
[24]	Zhao L, Peng Y, He S, et al. Apatinib induced ferroptosis by lipid peroxidation in gastric cancer[J]. Gastric Cancer, 2021, 24(3): 642-654. DOI:10.1007/s10120-021-01159-8. pmid: 33544270
[25]	Li D, Wang Y, Dong C, et al. CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stabi-lity via OTUB1[J]. Oncogene, 2023, 42(2): 83-98. DOI:10.1038/s41388-022-02537-x.
[26]	王宁宁, 孙明军, 田百玲. miRNA在Hp感染相关胃癌中作用的研究进展[J]. 山东医药, 2019, 59(10): 93-96. DOI:10.3969/j.issn.1002-266X.2019.10.027.
[27]	陶清. 胃癌上皮间质转化关键基因TNS1的识别和验证及临床关联研究[D]. 镇江: 江苏大学, 2020. DOI:10.27170/d.cnki.gjsuu.2020.000957.
[28]	Choi EH, Kim JT, Kim JH, et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer[J]. Clin Chim Acta, 2009, 406(1/2): 45-51. DOI:10.1016/j.cca.2009.05.008.

CST1在胃癌进展中的作用机制及临床意义

Mechanism of action and clinical significance of CST1 in the progression of gastric cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[4]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[5]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[6]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[7]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[8]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[9]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[10]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[11]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[12]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩. 人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.
[13]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[14]	李立立, 安有志, 王艳军. 替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例[J]. 国际肿瘤学杂志, 2022, 49(7): 444-446.
[15]	杨娅, 宁晓飞, 李炳亮, 姚慧, 山长平, 吕敏. 原花青素通过诱导活性氧产生介导抗SNU-1胃癌细胞株的作用机制研究[J]. 国际肿瘤学杂志, 2022, 49(5): 257-262.